Envestnet Asset Management Inc. Sells 7,553 Shares of Stryker Co. (NYSE:SYK)

Envestnet Asset Management Inc. lessened its stake in Stryker Co. (NYSE:SYK) by 1.2% during the 4th quarter, Holdings Channel.com reports. The firm owned 625,134 shares of the medical technology company’s stock after selling 7,553 shares during the quarter. Envestnet Asset Management Inc.’s holdings in Stryker were worth $225,079,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Kohmann Bosshard Financial Services LLC bought a new stake in shares of Stryker in the 4th quarter valued at about $25,000. Dunhill Financial LLC lifted its position in Stryker by 94.9% during the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock valued at $27,000 after acquiring an additional 37 shares during the last quarter. Rakuten Securities Inc. boosted its stake in Stryker by 618.2% in the fourth quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company’s stock valued at $28,000 after acquiring an additional 68 shares in the last quarter. Centricity Wealth Management LLC purchased a new position in Stryker in the fourth quarter worth $30,000. Finally, BankPlus Trust Department acquired a new position in shares of Stryker during the fourth quarter worth $33,000. 77.09% of the stock is currently owned by institutional investors.

Insider Transactions at Stryker

In other news, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the transaction, the director now owns 3,642,075 shares in the company, valued at $1,428,567,498. The trade was a 5.24 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Allan C. Golston sold 2,458 shares of the company’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the sale, the director now directly owns 14,895 shares of the company’s stock, valued at $5,705,827.65. This represents a 14.16 % decrease in their position. The disclosure for this sale can be found here. Insiders own 5.50% of the company’s stock.

Stryker Stock Performance

NYSE SYK opened at $346.14 on Monday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. The stock’s 50 day simple moving average is $381.69 and its 200-day simple moving average is $374.39. The company has a market cap of $132.12 billion, a PE ratio of 44.61, a price-to-earnings-growth ratio of 2.93 and a beta of 0.95. Stryker Co. has a 1-year low of $314.93 and a 1-year high of $406.19.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period last year, the company posted $3.46 EPS. As a group, equities research analysts anticipate that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 0.97%. The ex-dividend date of this dividend is Monday, March 31st. Stryker’s dividend payout ratio (DPR) is 43.30%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on SYK shares. Needham & Company LLC restated a “buy” rating and set a $442.00 price target on shares of Stryker in a research note on Friday, March 21st. Citigroup restated a “buy” rating and set a $450.00 price target on shares of Stryker in a research note on Wednesday, February 26th. Canaccord Genuity Group boosted their price objective on shares of Stryker from $420.00 to $435.00 and gave the company a “buy” rating in a report on Wednesday, January 29th. The Goldman Sachs Group set a $422.00 target price on Stryker in a research note on Tuesday, March 4th. Finally, Stifel Nicolaus boosted their price target on Stryker from $400.00 to $440.00 and gave the company a “buy” rating in a research note on Wednesday, January 29th. Five research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $421.90.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.